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Background: Immunoassays are widely used in clinical laboratories for measurement of plasma/serum concentrations
of steroid hormones such as cortisol and testosterone. Immunoassays can be performed on a variety of standard
clinical chemistry analyzers, thus allowing even small clinical laboratories to do analysis on-site. One limitation of steroid
hormone immunoassays is interference caused by compounds with structural similarity to the target steroid of the
assay. Interfering molecules include structurally related endogenous compounds and their metabolites as well as drugs
such as anabolic steroids and synthetic glucocorticoids.
Methods: Cross-reactivity of a structurally diverse set of compounds were determined for the Roche Diagnostics
Elecsys assays for cortisol, dehydroepiandrosterone (DHEA) sulfate, estradiol, progesterone, and testosterone.
These data were compared and contrasted to package insert data and published cross-reactivity studies for other
marketed steroid hormone immunoassays. Cross-reactivity was computationally predicted using the technique of
two-dimensional molecular similarity.
Results: The Roche Elecsys Cortisol and Testosterone II assays showed a wider range of cross-reactivity than the DHEA
sulfate, Estradiol II, and Progesterone II assays. 6-Methylprednisolone and prednisolone showed high cross-reactivity for
the cortisol assay, with high likelihood of clinically significant effect for patients administered these drugs. In addition,
21-deoxycortisol likely produces clinically relevant cross-reactivity for cortisol in patients with 21-hydroxylase deficiency,
while 11-deoxycortisol may produce clinically relevant cross-reactivity in 11β-hydroxylase deficiency or following
metyrapone challenge. Several anabolic steroids may produce clinically significant false positives on the testosterone
assay, although interpretation is limited by sparse pharmacokinetic data for some of these drugs. Norethindrone therapy
may impact immunoassay measurement of testosterone in women. Using two-dimensional similarity calculations, all
compounds with high cross-reactivity also showed a high degree of similarity to the target molecule of the immunoassay.
Conclusions: Compounds producing cross-reactivity in steroid hormone immunoassays generally have a high degree
of structural similarity to the target hormone. Clinically significant interactions can occur with structurally similar drugs
(e.g., prednisolone and cortisol immunoassays; methyltestosterone and testosterone immunoassays) or with endogenous
compounds such as 21-deoxycortisol that can accumulate to very high concentrations in certain disease conditions.
Simple similarity calculations can help triage compounds for future testing of assay cross-reactivity.
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Immunoassays are frequently used in laboratory medicine
for quantitation of plasma/serum concentrations of ster-
oid hormones such as cortisol, dehydroepiandrosterone
(DHEA) sulfate, estradiol, progesterone, or testosterone
[1,2]. A variety of immunoassay methods are available, ran-
ging from enzyme-linked immunosorbent assays (ELISAs)
to homogeneous immunoassays that can be run on high-
throughput analyzers commonly found in hospital clinical
laboratories [3]. The most common alternative approach
for measurement of steroid hormones is chromatog-
raphy (especially high-performance liquid chromatography,
HPLC), either alone or in combination with mass spec-
trometry (MS) (HPLC/MS or simply LC/MS) [4-7]. An
increasing number of clinical laboratories, particularly
reference laboratories, utilize liquid chromatography-
tandem mass spectrometry (LC/MS/MS) for steroid
hormone measurement [5]. LC/MS/MS provides a high
degree of specificity for steroid hormone measurement.
However, chromatography and mass spectrometry require
specialized technical skill along with dedicated and often
expensive instrumentation. Consequently, many clinical
laboratories continue to use immunoassays for routine
steroid hormone measurement.
One limitation of steroid hormone immunoassays is
interference caused by compounds with structural simi-
larity to the target steroid molecule against which the
assay antibodies were generated [8]. Interfering molecules
can be structurally related endogenous compounds (e.g.,
6β-hydroxycortisol for a cortisol assay), drugs (including
anabolic steroids and herbal medications), or natural
products. Metabolites of these compounds may add-
itionally cross-react. The manufacturers of commercially
marketed steroid hormone immunoassays test a variety of
endogenous and synthetic hormones for cross-reactivity
and report this data in the assay package insert, typically
as percent cross-reactivity or sometimes qualitatively (e.g.,
using a descriptor such as “cross-reacts”). The extent of
cross-reactivity testing varies by assay and manufacturer
without a clearly defined standard for which and how
many compounds to test [8,9].
While the package inserts or other manufacturers’ docu-
ments collectively contain extensive data on marketed
steroid hormone immunoassay cross-reactivity, studies of
previously unreported interference with steroid hormone
immunoassays have also appeared in the scientific litera-
ture. Examples include cross-reactivity of DHEA sulfate
with testosterone immunoassays [10,11], mifepristone with
estradiol and testosterone enzyme immunoassays [12], and
methylprednisolone with cortisol immunoassays [13].
In this study, we determine cross-reactivity of a variety
of steroid and steroidal compounds (including anabolic
steroids) to the Roche Diagnostics Elecsys immunoassays
for cortisol, DHEA sulfate, estradiol, progesterone, andtestosterone, and compare these results to other cross-
reactivity studies. We additionally utilize computational
methodology to attempt to predict cross-reactivity of com-
pounds for steroid hormone immunoassays, building on
previous work using similarity analysis to predict cross-
reactivity of drug of abuse and therapeutic drug monitoring
assays [14-17]. Our hypothesis is that a given compound
is more likely to cross-react with an immunoassay if the
compound shares a high level of structural similarity
to the target molecule/hapten of the assay. To our
knowledge, similarity analysis has not been applied to
the prediction of cross-reactivity of immunoassays used
to measure steroid hormones. Lastly, we discuss cross-
reactivity mostly likely to have impact on clinical testing
using steroid hormone immunoassays.Methods
Chemicals
Test compounds were obtained from Steraloids (Providence,
Rhode Island, USA) or Sigma-Aldrich (St. Louis, Missouri,
USA) (see Additional file 1 for sources and product
numbers for all compounds tested). Interference studies
were designed from NCCLS Guideline EP7-A [18], with
test compounds spiked into normal human plasma.
Each spiked sample was compared to the unadulterated
sample, with the degree of interference expressed as
percent cross-reactivity.Cross-reactivity Studies
The assays tested experimentally were the Roche Diagnostics
(Indianapolis, IN, USA) Cortisol, DHEA sulfate, Estradiol
II, Progesterone II, and Testosterone II assays for Elecsys
and Modular E170 analyzers. All assays were run using
manufacturer specifications on Modular E170 analyzers.
The complete details on assays are in the Additional
file 1. Cross-reactivity was grouped into four broad cat-
egories: Strong Cross-Reactivity (5% or greater), Weak
Cross-Reactivity (0.5-4.9%), Very Weak Cross-Reactivity
(0.05-0.49%), and Not Cross-Reactive (<0.05%). Percent
cross-reactivity is defined as the ratio of observed “steroid”
to the amount of test compound added, multiplied by
100. These categories do not imply clinical significance
but provide a broad framework to compare degree of
cross-reactivity.
To estimate clinical significance of cross-reactivity, a
literature search was conducted for studies that have re-
ported plasma/serum concentrations of the potentially
cross-reactive compounds. These included pharmacokinetic
studies of steroidal drugs or investigations of steroid hor-
mone concentrations in disorders such as 11β-hydroxylase
or 21-hydroxylase deficiency. These references are reported
in Tables 1, 2, 3, 4 and 5.
Table 1 Cortisol immunoassay cross-reactivity






• 62 – 194 ng/mL (morning) [19] 100% High (assay target)
• 23 – 119 ng/mL (afternoon) [19]











Prednisolone Up to 400 ng/mL in pediatric transplant
patients [21]
148% High
21-Deoxycortisol • 0.28 – 0.43 ng/mL (pediatric controls) [22] 45.4%
(package insert)
Low, except in patients with 21-hydroxylase
deficiency
• Up to 140 ng/mL (patients with
21-hydroxylase deficiency) [22]
Fludrocortisone • 0.36 ng/ml after single dose [23] 7.7% Low
5β-Dihydrocorticosterone Unknown 4.9% Unknown, serum/plasma concentrations not
reported
Corticosterone • 0.18 – 2.0 ng/mL (18 years and younger) [24] 4.6% Low
• 0.53 – 1.6 ng/mL (<18 years) [24]
11-Deoxycortisol • 0.17 – 1.8 ng/mL (pediatric controls) [22] 4.6% Low, except in patients following metyrapone
challenge or who have 11β-hydroxylase deficiency
• Up to 63 ng/mL (patients with
11β-hydroxylase deficiency) [22]
• Up to 250 ng/mL (following
metyrapone challenge) [25]
Canrenone 10 – 1,000 ng/mL in patients receiving
spironolactone [26-28]
1.8% Low, except if cortisol measured during peak
canrenone concentrations
17-Hydroxyprogesterone • 0.08 – 2.0 ng/mL (pediatric controls) [22] 1.6% Low, except in patients with 21-hydroxylase
deficiency
• Up to 1,005 ng/mL (21-hydroxylase
deficiency) [22]
Formestane Up to 14 ng/mL in breast cancer patients [29] 1.2% Low
Androstenedione • Up to 0.86 ng/mL before onset of puberty [30] 0.9% Low
• Up to 3.2 ng/mL in 21-hydroxylase
deficiency [30]
Prednisone Up to 57 ng/mL in pediatric transplant
patients receiving prednisolone [21]
0.3% Low
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Comparison of similarity of test molecules to the target
compounds of the steroid immunoassays used two-
dimensional (2D) similarity analysis, which determines
the similarity between molecules independent of any
in vitro data [52-54]. These methods have been applied
in our previous publications on cross-reactivity of drug
of abuse and therapeutic drug monitoring immunoassays
[14-17]. 2D similarity searching used the “find similar
molecules by fingerprints” protocol in Discovery Studio
versions 2.5.5 and 3.5 (Accelrys, Inc., San Diego, California,
USA). MDL public keys (a specific 2D similarity algorithm)
were used with the Tanimoto similarity coefficient (ranging
from 0 to 1 with 1 being maximally similar and 0 being
maximally dissimilar) and an input query. It should benoted that 2D similarity algorithms do not distinguish
between diastereomers and enantiomeric pairs. 2D simi-
larity for each test compound was compared to the target
molecule of the immunoassay (e.g., estradiol or progester-
one) undergoing analysis. Figure 1 illustrates 2D similarity
of five compounds to cortisol.Results
Cortisol immunoassay
Based on package insert data and the experimental test-
ing in the current study, six compounds produce cross-
reactivity of 5% of greater on the Roche Elecsys Cortisol
assay at a test concentration of 1 μg/mL (1,000 ng/mL):
6β-hydroxycortisol, allotetrahydrocortisol, 21-deoxycortisol,
Table 2 DHEA sulfate immunoassay cross-reactivity




DHEA sulfate • Up to 6,070 ng/mL (infants) [31] 100% High (assay target)
• 5 – 4,070 ng/mL (females > 1 year old) [31]
• 5–4,920 ng/mL (males > 1 year old) [31]
Pregnenolone sulfate • 21 – 84 ng/mL (adult controls) [32] 2.1% Low, possible minor effect around
time of parturition.
• Up to 1,580 ng/mL in pregnancy [33]
17-Hydroxyprogesterone • 0.1 – 2.0 ng/mL (pediatric controls) [22] 0.08% Low, possible minor effect in
21-hydroxylase deficiency.
• Up to 1,005 ng/mL (21-hydroxylase deficiency) [22]
17-Hydroxypregnenolone • Up to 4.3 ng/ml in healthy females [34,35] 0.05% Low
• Up to 4.8 ng/mL in healthy males [34,35]
• Up to 100 ng/mL in premature infants [36]
Krasowski et al. BMC Clinical Pathology 2014, 14:33 Page 4 of 13
http://www.biomedcentral.com/1472-6890/14/33fludrocortisone, prednisolone, and 6-methylprednisolone
(Figure 1; Table 1; Additional file 1). Seventeen additional
compounds produced cross-reactivity between 0.5 and
4.9%.
Using the cross-reactivity values, the apparent cortisol
concentration that could be produced on the Roche Elecsys
immunoassay was estimated for compounds based on pub-
lished serum/plasma concentrations, if available (Figure 2A,
Table 1). Prednisolone and 6-methylprednisolone are
both predicted to produce substantial apparent cortisol
concentrations on the Roche immunoassay at serum/
plasma concentrations typical in patients administered
these drugs. Falsely elevated cortisol readings may also
occur with 21-deoxycortisol in patients with 21-hydroxylase
deficiency and with 11-deoxycortisol following metyrapone
challenge (Figure 2A, Table 1). In both scenarios, clinically
significant falsely elevated cortisol measurements are most
likely only when 21-deoxycortisol or 11-deoxycortisol are at
the high end of serum/plasma concentrations reported in
the literature.
The majority of the compounds with strong cross-
reactivity for the Roche Elecsys Cortisol assay had 2D-
similarities to cortisol of 0.867 or higher (Figure 2B).
Only one compound (tetrahydrocortisone) had a 2D-Table 3 Estradiol immunoassay cross-reactivity
Compound Plasma/serum concentrations
Estradiol (endogenous compound) • 0.01 – 0.04 ng/mL (males) [37]
• 0.013 – 0.50 ng/mL (premenopausal f
• Up to 4.3 ng/mL (pregnancy) [37]
Estrone • Up to 0.06 ng/mL (males) [24]
• Up to 0.2 ng/mL (females) [24]
Ethinyl estradiol Up to 0.1 ng/mL while on medication
Estriol • Up to 18 ng/mL in pregnancy [42]
• Up to 2.4 ng/mL in non-pregnant femsimilarity to cortisol higher than 0.867 but was not
cross-reactive in our study.
DHEA sulfate immunoassay
No compounds produced greater than 5% cross-reactivity
on the Roche Elecsys DHEA sulfate immunoassay at a
test concentration of 50 μg/mL (50,000 ng/mL), and
only two compounds (estropipate and pregnenolone
sulfate) produced greater than 0.5% cross-reactivity (Table 2;
Additional file 1). Twenty-six compounds produced cross-
reactivity between 0.05 and 0.5%. This group of compounds
with very weak cross-reactivity included anabolic steroids
(nandrolone), androstanes (androstenedione, androsterone
sulfate), estranes (estrone-3-sulfate), and pregnanes (17α-
hydroxypregnenolone).
Using the cross-reactivity values, the apparent DHEA
sulfate concentration that could be produced on the Roche
Elecsys immunoassay was estimated for compounds based
on published serum/plasma concentrations, if available
(Figure 3A, Table 2). In only two scenarios was the apparent
DHEA sulfate concentration predicted to fall within the
reference ranges for DHEA sulfate – pregnenolone sulfate
in pregnancy and 17-hydroxyprogesterone in patients with








0.09% Possible contribution in pregnancy
ales [43]
Table 4 Progesterone immunoassay cross-reactivity




Progesterone • 0.2 – 1.4 ng/mL (males) [44] 100% High (assay target)
• Up to 27 ng/mL (women) [44]
5β-Dihydroprogesterone Up to 0.8 ng/mL in adults [45] 18.2% Possible significant contribution for individuals
with progesterone concentrations on the
lower end of reference interval
17-Hydroxyprogesterone • 0.08 – 2.0 ng/mL (pediatric controls) [22] 1.2% Low, except in patients with
21-hydroxylase deficiency
• Up to 1,005 ng/mL
(21-hydroxylase deficiency) [22]
Pregnanolone Up to 17 ng/mL in women [33] 0.90% Low
Allopregnanolone Up to 29 ng/mL in women [33] 0.82% Low
Medroxyprogesterone Up to 100 ng/mL following
dosing in women [46]
0.67% Possible significant contribution for individuals
with progesterone concentrations on the
lower end of reference interval
Corticosterone • 0.18 – 2.0 ng/mL (18 years and younger) [24] 0.54% Low
• 0.53 – 1.6 ng/mL (<18 years) [24]
11-Deoxycortisol • 0.17 – 1.8 ng/mL (pediatric controls) [22] 0.39% Low, except in patients following
metyrapone challenge or who have
11β-hydroxylase deficiency• Up to 63 ng/mL (11β-hydroxylase deficiency) [22]
• Up to 250 ng/mL (metyrapone challenge) [25]
Nandrolone Up to 5.16 ng/mL in men following intramuscular
injection [47]
0.17% Low
Pregnenolone Up to 3.27 ng/mL in women [33] 0.12% Low
Exemestane Up to 441 ng/mL in post-menopausal women [48] 0.09% Possible significant effect if progesterone
measured near peak of exemestane
plasma concentration
Androstenedione • Up to 0.86 ng/mL before onset of puberty [30] 0.09% Low
• Up to 3.2 ng/mL in 21-hydroxylase deficiency [30]
Table 5 Testosterone immunoassay cross-reactivity






• 0 – 10 ng/mL (males) [49] 100% High (assay target)
• 0 – 0.5 ng/mL (females) [49]
Methyltestosterone Up to 40 ng/mL following single
dose [50]
12.2% High, especially if measured during peak concentration
Boldenone Up to 1.1 ng/mL in horses following
dosing [51]
7.2% Likely low, although there is lack of human pharmacokinetic
data
19-Norclostebol Unknown 6.7% Unknown, no human pharmacokinetic data available
Norethindrone Up to 20 ng/mL while on medication
[39-41]
6.7% Possible significant contribution in women taking
norethindrone, especially if specimen drawn near
peak of norethindrone concentration
11β-Hydroxytestosterone Unknown 5.5% Unknown, no human pharmacokinetic data available
Methandrostenolone Unknown 5.4% Unknown, no human pharmacokinetic data available
Normethandrolone Unknown 5.4% Unknown, no human pharmacokinetic data available
Nandrolone Up to 5.16 ng/mL [47] 2.1% Low
Androstenedione • Up to 0.86 ng/mL before onset of
puberty [30]
1.2% Low
• Up to 3.2 ng/mL in 21-hydroxylase
deficiency [30]
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Figure 1 Illustration of two-dimensional similarity to cortisol. The
figure depicts chemical structures of cortisol, 6-methylprednisolone,
21-deoxycortisol, 17α-hydroxyprogesterone, boldenone, and mesterolone.
Below each compound is the two-dimensional similarity to cortisol and
the degree of cross-reactivity to the Roche Elecsys Cortisol immunoassay.
Figure 2 Cortisol immunoassay cross-reactivity and similarity
predictions. A. The plot shows the cortisol reference range for
adults (highlighted in yellow) in comparison to the predicted
apparent cortisol concentrations produced on the Roche Elecsys
Cortisol assay by 6-methylprednisolone, prednisolone, 21-deoxycortisol
(healthy controls and patients with 21-hydroxylase deficiency), and
11-deoxycortisol (healthy controls, patients with 11β-hydroxylase
deficiency, and following metyapon challenge). Table 1 contains
the concentration ranges and percent cross-reactivity values from
which the estimated apparent cortisol concentrations are derived.
B. Two-dimensional similarity of compounds to cortisol is shown,
sorted by degree of cross-reactivity in the Roche Cortisol assay
(horizontal line in each column indicates average similarity within that
group). Similarity values vary from 0 to 1, with 1 being maximally similar.
The compounds are subdivided into categories of strong cross-reactivity
(5% or greater, black circles), weak cross-reactivity (0.5-4.9%, red
squares), very weak cross-reactivity (0.05-0.49%, blue triangles), and
no cross-reactivity (<0.05%, green diamonds) to the Roche Cortisol
assay (complete list of compounds and associated cross-reactivities
and 2D similarities is in Additional file 1).
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reactivity in the DHEA sulfate immunoassay (estropipate
and pregnenolone sulfate) had higher 2D similarities to
DHEA sulfate than all 56 compounds classified as non-
cross-reactive (Figure 3B; Additional file 1). Only 4 of 20
compounds with very weak cross-reactivity has 2D similar-
ity to DHEA sulfate greater than 0.8. All non-cross-reactive
compounds had 2D similarities less than 0.8.
Estradiol immunoassay
Only estrone (0.54%) produced greater than 0.5% cross-
reactivity on the Roche Elecsys Estradiol II immunoassay at
a challenge of 1 μg/mL (1,000 ng/mL) (Table 3; Additional
file 1). Estriol, estropipate, ethinyl estradiol, 2-methoxy-
estradiol, 17β-estradiol-17-valerate, and 17β-estradiol-3,
17-disulfate each produced very weak cross-reactivity be-
tween 0.05 and 0.5%. The aromatase inhibitors exemestane,
formestane, and letrozole produced no detectable cross-
reactivity.Using the cross-reactivity values, the apparent estradiol
concentration that could be produced on the Roche
Elecsys immunoassay was estimated for compounds
based on published serum/plasma concentrations, if avail-
able (Figure 4A, Table 3). No compound was predicted to
Figure 3 DHEA sulfate immunoassay cross-reactivity and similarity
predictions. A. The plot shows the DHEA sulfate reference range for
males greater than 1 year old, females greater than 1 year old,
and infants in comparison to the predicted apparent DHEA sulfate
concentrations produced on the Roche Elecsys DHEA sulfate
assay by pregnenolone sulfate (healthy controls and in pregnancy),
17-hydroxyprogesterone (pediatric controls and patients with
21-hydroxylase deficiency), and 17-hydroxypregnenolone (healthy
controls and premature infants). Table 2 contains the concentration
ranges and percent cross-reactivity values from which the estimated
apparent DHEA sulfate concentrations are derived. B. Two-dimensional
similarity of compounds to DHEA sulfate is shown, sorted by degree of
cross-reactivity in the Roche DHEA sulfate assay (horizontal line in each
column indicates average similarity within that group). Similarity values
vary from 0 to 1, with 1 being maximally similar. The compounds are
subdivided into categories of strong cross-reactivity (5% or greater,
black circles), weak cross-reactivity (0.5-4.9%, red squares), very weak
cross-reactivity (0.05-0.49%, blue triangles), and no cross-reactivity
(<0.05%, green diamonds) to the Roche DHEA sulfate assay (complete
list of compounds and associated cross-reactivities and 2D similarities
is in Additional file 1).
Figure 4 Estradiol immunoassay cross-reactivity and similarity
predictions. A. The plot shows the estradiol reference ranges for
males, non-pregnant females, and pregnant females (highlighted in
yellow) in comparison to the predicted apparent estradiol concentrations
produced on the Roche Elecsys Estradiol II assay by estrone (females),
ethinyl estradiol, and estriol (non-pregnant and pregnant females). Table 3
contains the concentration ranges and percent cross-reactivity values
from which the estimated apparent estradiol concentrations are derived.
B. Two-dimensional similarity of compounds to estradiol is shown, sorted
by degree of cross-reactivity in the Roche Estradiol II assay
(horizontal line in each column indicates average similarity within
that group). Similarity values vary from 0 to 1, with 1 being maximally
similar. The compounds are subdivided into categories of strong
cross-reactivity (5% or greater, black circles), weak cross-reactivity
(0.5-4.9%, red squares), very weak cross-reactivity (0.05-0.49%, blue
triangles), and no cross-reactivity (<0.05%, green diamonds) to the
Roche Estradiol II assay (complete list of compounds and associated
cross-reactivities and 2D similarities is in Additional file 1).
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range for males or females. Even estriol, which can reach
high concentrations in pregnancy, likely produces little orno clinically significant impact on the Roche estradiol im-
munoassay due to low cross-reactivity. The 2D similarities
of estrone (0.882), ethinyl estradiol (0.943), and estriol
(0.917) were higher than any of the compounds that were
not cross-reactive on the Roche assay (Figure 4B).
Figure 5 Progesterone immunoassay cross-reactivity and
similarity predictions. A. The plot shows the progesterone
reference range for adult males and females (highlighted in
yellow) in comparison to the predicted apparent progesterone
concentrations produced on the Roche Elecsys Progesterone II
assay by 5β-dihydroprogesterone, 17-hydroxyprogesterone
(pediatric controls and patients with 21-hydroxylase deficiency),
pregnanolone, allopregnanolone, medroxyprogesterone, 11-
deoxycortisol (healthy controls, patients with 11β-hydroxylase
deficiency, and following metyapon challenge), and exemestane.
Table 4 contains the concentration ranges and percent cross-reactivity
values from which the estimated apparent progesterone concentrations
are derived. B. Two-dimensional similarity of compounds to
progesterone is shown, sorted by degree of cross-reactivity in the
Roche Progesterone II assay (horizontal line in each column indicates
average similarity within that group). Similarity values vary from 0 to 1,
with 1 being maximally similar. The compounds are subdivided into
categories of strong cross-reactivity (5% or greater, black circles), weak
cross-reactivity (0.5-4.9%, red squares), very weak cross-reactivity (0.05-
0.49%, blue triangles), and no cross-reactivity (<0.05%, green diamonds)
to the Roche Progesterone II assay (complete list of compounds and
associated cross-reactivities and 2D similarities is in Additional file 1).
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5β-Dihydroprogesterone (5β-pregnan-3,20-dione) was the
most cross-reactive compound for the Roche Elecsys
Progesterone II immunoassay at a challenge of 1 μg/mL
(1,000 ng/mL), with a cross-reactivity of 18.2% (Table 4;
Additional file 1). 17-Hydroxyprogesterone, 5α-pregnan-
3-ol-20-one, 5α-pregnan-3,20-dione, 5α-pregnenolone,
medroxyprogesterone, and pregnanolone each produced
weak cross-reactivity between 0.5% and 4.9%. An additional
twenty-two compounds produced very weak cross-reactivity
(0.05-0.49%).
Using the cross-reactivity values, the apparent progester-
one concentration that could be produced on the Roche
Elecsys immunoassay was estimated for compounds based
on published serum/plasma concentrations, if available
(Figure 5A, Table 4). The most significant apparent pro-
gesterone concentrations were estimated to occur with
17-hydroxyprogesterone in patients with 21-hydroxylase
deficiency and for 11-deoxycortisol following metyrapone
challenge. 5β-Dihydroprogesterone and allopregnano-
lone both may produce apparent progesterone concen-
trations of approximately 0.2 ng/mL, but likely only
when these compounds are the highest end of what
can occur physiologically (Table 4). Two medications,
medroxyprogesterone and exemestane, each may have
cross-reactivity on the progesterone immunoassay that
can produce apparent progesterone concentration of
approximately 0.5 ng/mL.
5β-Dihydroprogesterone had higher 2D similarity to
progesterone than any compound that was not cross-
reactive (Figure 5B; Additional file 1). All compounds
with strong or weak cross-reactivity had 2D similarities
of 0.722 or higher to progesterone. In contrast, only 27
of 55 compounds that were non-cross-reactive on the
Roche progesterone immunoassay had 2D similarity of
0.722 or higher to progesterone.
Testosterone immunoassay
Anabolic steroids were well-represented among com-
pounds cross-reacting with the Roche Elecsys Testosterone
II immunoassay at a test concentration of 0.1 μg/mL
(100 ng/mL) (Table 5; Additional file 1). Seven compounds
(boldenone, 19-norclostebol, dianabol, methyltestosterone,
norethindrone, normethandrolone, and 11β-hydroxytes-
tosterone) produced cross-reactivity of 5% or greater.
Nine additional compounds produced cross-reactivity
between 0.5% and 4.9%. Examples of anabolic steroids
that produced no detectable cross-reactivity included
anasterone (oxymetholone), stanozolol, and turinabol.
Using the cross-reactivity values, the apparent testos-
terone concentration that could be produced on the
Roche Elecsys Testosterone II immunoassay was estimated
for compounds based on published serum/plasma concen-
trations, if available (Figure 6A, Table 5). There is limited
Figure 6 Testosterone immunoassay cross-reactivity and similarity
predictions. A. The plot shows the testosterone reference range for
males and females (highlighted in yellow) in comparison to the
predicted apparent testosterone concentrations produced on the Roche
Elecsys Testosterone II assay by methyltestosterone, norethindrone,
nandrolone, and androstenedione (healthy controls and patients with
21-hydroxylase deficiency). Table 5 contains the concentration ranges
and percent cross-reactivity values from which the estimated apparent
testosterone concentrations are derived. B. Two-dimensional similarity
of compounds to testosterone is shown, sorted by degree of
cross-reactivity in the Roche Testosterone II assay (horizontal line in
each column indicates average similarity within that group). Similarity
values vary from 0 to 1, with 1 being maximally similar. The compounds
are subdivided into categories of strong cross-reactivity (5% or greater,
black circles), weak cross-reactivity (0.5-4.9%, red squares), very weak
cross-reactivity (0.05-0.49%, blue triangles), and no cross-reactivity
(<0.05%, green diamonds) to the Roche Testosterone II assay
(complete list of compounds and associated cross-reactivities and
2D similarities is in Additional file 1).
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some of the anabolic steroids, with generally more
focus on measurement of these compounds in urine
samples, usually for the purposes of detecting use asperformance-enhancing drugs in competitive athletics
[55-57]. Of the anabolic steroids for which serum/plasma
concentrations are available, methyltestosterone appears
to be the one most likely to impact testosterone im-
munoassay measurements in males. Norethindrone and
nandrolone could produce clinically significant impact
on testosterone measurement in women, as may andro-
stenedione in patients with 21-hydroxylase deficiency
(Figure 6A, Table 5).
All but one compound (testosterone propionate) that
had cross-reactivity of 0.05% or greater on the Roche
assay had 2D similarities to testosterone of 0.8 or greater
(Figure 6B). Only 20 of 59 compounds that were non-
cross-reactive on the Roche testosterone immunoassay
had 2D similarity of 0.8 or higher to testosterone.
Discussion
Immunoassays are commonly used clinically for meas-
urement of steroid hormone serum/plasma concentra-
tions. In many situations, immunoassays produce results
comparable to the more specific chromatography/mass
spectrometry-based methods. However, a growing number
of studies have documented differences between immuno-
assays and mass spectrometry methods (especially LC/
MS/MS) [6,7,58-63]. Some differences can be attributed
to lower limit of quantitation issues with immunoassays,
especially for analytes that may be very low in concentra-
tion in some populations (e.g., testosterone in females
or estradiol in males). Cross-reactivity to endogenous
or exogenous compounds other than the target steroid
hormone of the assay may also contribute to differences
between immunoassay and LC/MS/MS [4,7,34,60,61].
In this study, we focused on cross-reactivity of Roche
Elecsys immunoassays for five steroid hormones (cortisol,
DHEA sulfate, estradiol, progesterone, and testosterone).
Previous studies have demonstrated significant cross-
reactivity of marketed cortisol immunoassays [13,61]. Our
studies suggest that false positive cortisol measurements
are most likely on the Roche assay during treatment with
prednisolone or 6-methylprednisolone, in 21-hydroxylase
deficiency due to elevated 21-deoxycortisol, or following
metyrapone challenge due to 11-deoxycortisol. This is in
accord with package insert data [19]. A study comparing
cortisol measurement by immunoassay on the Siemens
ADVIA Centaur XP analyzer versus LC/MS/MS demon-
strated substantial positive bias of the immunoassay fol-
lowing metyrapone challenge, attributable to interference
on the cortisol immunoassay from 11-deoxycortisol [61].
To our knowledge, other than package insert data
[31], there is no published data on specificity of DHEA
sulfate immunoassays. Our data suggests that cross-
reactivity is likely not a major issue with the Roche
Elecsys assay. In only two scenarios was cross-reactivity
predicted to produce false positive DHEA sulfate values
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sulfate in pregnancy and 17-hydroxyprogesterone in
21-hydroxylase deficiency. In each of these cases, the
contribution is likely minor even at maximally predicted
interference levels.
A number of studies have compared immunoassay ver-
sus mass spectrometry for measurement of plasma/serum
estradiol. Estradiol immunoassays often do not perform
well relative to LC/MS/MS in measuring the lower end of
estradiol concentrations found in males, a limitation likely
related primarily to differing lower limits of quantitation
between the methods [59,62,64,65]. There have been few
reports of interferences with estradiol immunoassays.
Negative interference by estriol has been reported in a
study of the Abbott AxSYM estradiol immunoassay [66].
No significant interference by estrone or estriol was noted
in a study of the Abbott Architect estradiol assay [64].
Our cross-reactivity studies suggest that clinically signifi-
cant cross-reactivity with the Roche Elecsys Estradiol II is
unlikely, similar to package insert data [37].
Compared to assays for estradiol and testosterone, there
has been relatively little comparative study of progesterone
immunoassays with mass spectrometry-based methods.
A comparison of 12 progesterone immunoassays with
gas chromatography/mass spectrometry (GC/MS) dem-
onstrated high variability in specificity and sensitivity of
the immunoassays compared to GC/MS [58]. In our study
of the Roche Elecsys Progesterone II immunoassay, the
most significant apparent progesterone concentrations
were estimated to occur with 17-hydroxyprogesterone
in patients with 21-hydroxylase deficiency and for 11-
deoxycortisol following metyrapone challenge. Medroxy-
progesterone and exemestane each may produce apparent
progesterone of approximately 0.5 ng/mL. 5β-Dihydropro-
gesterone and allopregnanolone both may produce
apparent progesterone concentrations in the range of
0.2 ng/mL. However, with the exception of 17-hydroxy-
progesterone in patients with 21-hydroxylase deficiency,
none of the other interferences likely produce high
enough interference to cause diagnostic issues in women,
where progesterone concentrations typically exceed 1 ng/
mL. There is the possibility that these interferences could
cause significant interference in progesterone measure-
ments in males, although progesterone is typically infre-
quently measured in males. Doping with exemestane and
other aromatase inhibitors has been reported in competi-
tive athletes and others abusing anabolic steroids, primar-
ily as a means to counteract gynecomastia and side effects
related to aromatization of anabolic steroids by aromatase
[57]. Our results raise the possibility that surreptitious use
of aromatase inhibitors could interfere with some steroid
hormone measurements by immunoassays.
Anabolic steroids were well-represented among com-
pounds cross-reacting with the Roche Elecsys TestosteroneII immunoassay with six of these compounds (boldenone,
19-norclostebol, dianabol, methyltestosterone, normethan-
drolone, and 11β-hydroxytestosterone) producing cross-
reactivity of 5% or greater. Norethindrone, a progestogen
commonly found in oral contraceptives, also produced
strong cross-reactivity. Methyltestosterone, nandrolone,
and norethindrone all appear capable of causing clinically
significant false positives on the Roche testosterone assay,
especially in females. However, interpretation of the clinical
significance of the strong cross-reactivity of boldenone,
19-norclostebol, dianabol, normethandrolone, and 11β-
hydroxytestosterone on the testosterone assay is ham-
pered by lack of human pharmacokinetic data. We were
unable to locate reliable serum/plasma concentrations
for these compounds in humans. There is animal data
for some of these compounds [51], mainly due to inter-
est in detecting doping in animal sports such as horse
racing, but it is difficult to know how well these data
extrapolate to humans.
The results of this study raise interesting questions
about the structural differences of diagnostic antibodies
used for clinical measurement of steroid hormones. There
have been a number of studies looking at the three-
dimensional structure of antibodies that bind steroid
hormones. A crystallographic study of two different estra-
diol antibodies revealed that antibodies with equally high
specificity for estradiol relative to other steroids could,
nonetheless, have markedly different amino acid sequence,
ligand binding pockets, and ligand orientations [67]. Three
studies of anti-testosterone antibodies demonstrated how
directed mutagenesis could improve antibody specificity
[68-70]. For steroid hormones, it would be of interest to
compare and contrast the structure of antibodies used in
different marketed immunoassays.
Our results using 2D-similarity to predict steroid hor-
mone cross-reactivity show comparable findings to our
previous studies predicting cross-reactivity of drug of
abuse and therapeutic drug monitoring assays [14-17].
All compounds with strong cross-reactivity and most
with weak cross-reactivity had 2D similarity values of 0.8
or higher to the target steroid molecule of the assay.
Although there is some overlap in 2D similarity scores
between compounds with strong or weak cross-reactivity
and those with no cross-reactivity, use of a 2D similarity
cutoff such as 0.8 would help identify compounds with
high likelihood of showing strong cross-reactivity. Con-
versely, compounds with low 2D similarity (e.g., less
than 0.6) are unlikely to show strong or even weak
cross-reactivity. 2D Similarity calculations can thus be
used to prioritize compounds for future immunoassay
cross-reactivity studies for steroid hormones. This includes
novel anabolic steroids used for doping or other as yet
uncharacterized compounds, along with metabolites. There
are some compounds with high similarity to the target
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cross-reactivity. An example is tetrahydrocortisone for the
Roche Elecsys Cortisol immunoassay. It may be necessary
to use three-dimensional methods such as pharmacophores
or docking to understand why such compounds with strong
similarity do not cross-react [17,53,71].
Conclusions
Clinically significant cross-reactivity on steroid hormone
immunoassays generally occurs with structurally similar
drugs (e.g., prednisolone and cortisol immunoassays;
methyltestosterone and testosterone immunoassays) or
with endogenous compounds such as 21-deoxycortisol
that can accumulate to very high concentrations in certain
disease conditions. Compounds producing cross-reactivity
in steroid hormone immunoassays generally have a high
degree of structural similarity to the target hormone. Rela-
tive simple 2D similarity calculations can help triage com-
pounds for future testing of immunoassay cross-reactivity.
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